M. Marx et al., MODULATION OF PLATELET-DERIVED GROWTH-FACTOR RECEPTOR EXPRESSION IN MICROVASCULAR ENDOTHELIAL-CELLS DURING IN-VITRO ANGIOGENESIS, The Journal of clinical investigation, 93(1), 1994, pp. 131-139
Microvascular endothelial cells in vivo exhibit a plastic phenotype, f
orming a nonproliferative, differentiated capillary net-work, while re
taining their ability to respond to injury by proliferation, migration
and neovascularization. The presence of PDGF receptors and PDGF respo
nsiveness in microvascular endothelial cells and the significance of P
DGF isoforms in the control of endothelial cell growth and differentia
tion remain controversial. Since culture of microvascular endothelial
cells in a three-dimensional (3D) system induced cell differentiation
and angiogenesis and inhibited proliferation, the present study invest
igates the role of different extracellular matrix environments in indu
cing different microvascular endothelial cell phenotypes on microvascu
lar endothelial cell PDGF receptor expression and PDGF responsiveness.
In conventional two-dimensional (2D) culture, microvascular endotheli
al cells expressed both PDGF receptor alpha and beta chains. Suramin t
reatment demonstrated continuous downregulation of the alpha receptor
surface expression. PDGF BB and, to a lesser extent, PDGF AB were mito
genic in 2D-culture, PDGF AA failed to induce any proliferative respon
se despite inducing receptor autophosphorylation. During in vitro angi
ogenesis induced by 3D-culture, both PDGF receptors were rapidly downr
egulated. Assessment of cell proliferation showed quiescent cells and
PDGF unresponsiveness. We conclude that the induction of a differentia
ted phenotype during in vitro angiogenesis (tube formation) driven in
part by the spatial organization of the surrounding matrix is associat
ed with a downregulation of PDGF receptors. Identification of the mole
cular cell-matrix interactions involved in this receptor regulation ma
y allow for targeted manipulation of cell growth in vivo and lead to n
ovel therapeutic applications for PDGF.